Most of the conversation about retatrutide in Australia is about getting on it. Almost nobody is talking about what happens after — the maintenance question. And that question matters more than the headline number, because the same trials that made retatrutide famous also make it clear that these medicines work while you take them, not after you stop. If you're following retatrutide Australia news while waiting for the TGA to see a submission, this is the part worth thinking about now, not in 2028.

The timing hook is fresh: Eli Lilly confirmed on 3 August 2026 that a defined group of patients can now apply for early access to its investigational obesity drug, retatrutide, ahead of FDA approval, and the company said it plans to submit a biologics licence application for retatrutide to the FDA in the first quarter of 2027. That's a US pathway, not an Australian one — but it tells you the clock has started. Which means the smart Australian question is no longer only "when can I get it?" It's "what does year three look like?"

Why the maintenance question is the real one

Retatrutide's TRIUMPH-1 phase 3 result — up to roughly 28.3% average body weight loss at 12mg over 80 weeks, with 45.3% of participants losing 30% or more — is the largest weight change we've seen from an obesity medicine to date. But every one of those numbers is an on-treatment number. The trial measured people who were still receiving the drug.

We already have a clear signal from the earlier generation of incretin medicines about what happens when treatment ends. In the extension of the semaglutide STEP 1 trial, participants regained roughly two-thirds of the weight they'd lost within a year of stopping, and cardiometabolic markers drifted back toward baseline alongside it. Tirzepatide withdrawal studies pointed the same direction: continued treatment continued to help, withdrawal reversed a substantial share of the benefit.

There is no published long-term retatrutide withdrawal dataset yet. That's an honest gap, not a reassurance — it would be irresponsible to assume a triple agonist behaves differently just because it's more potent. If anything, a bigger loss means there is more to potentially regain. Anyone telling you otherwise is guessing.

What this means for Australians specifically

Here's where it gets local. In Australia, obesity medicines are overwhelmingly paid for out of pocket. Semaglutide and tirzepatide are not PBS-listed for weight management alone, which means the "keep taking it indefinitely" model is a household budget decision repeated every month, for years — for a condition that affects roughly two in three Australian adults.

So the Australian version of the maintenance question is partly clinical and partly financial: can you sustain the treatment, and if you can't, what's the plan? That's a conversation to have with a GP before starting any of these medicines, not after. Our Australian access and policy page tracks how the funding picture is moving, and what retatrutide actually is explains why a three-receptor drug isn't simply "a stronger Ozempic".

Questions worth taking to your GP

  • If this works for me, what does the long-term plan look like — dose reduction, maintenance dosing, or continuation?
  • What monitoring do I need if I lose a very large amount of weight quickly?
  • How do we protect lean mass and bone health during and after the loss phase?
  • If cost becomes unmanageable, what's the taper and support plan?

The scaffolding you can build now

You can't buy retatrutide in Australia today — it isn't TGA-approved and Lilly's regulatory filings are only beginning to move. But the things that make a result durable are things you can build for free, starting now:

Resistance training, twice a week minimum. Rapid weight loss on incretin drugs includes lean tissue. Strength work is the single best-evidenced way to protect it.

Protein at every meal. Standard advice in obesity medicine practice, and it becomes more important when appetite is suppressed and total intake drops.

Sleep and alcohol. Both quietly move appetite regulation, and neither is affected by which receptor a drug hits.

A relationship with a doctor who tracks your data. Weight, waist, blood pressure, lipids, HbA1c. When retatrutide eventually reaches Australia, the people with a documented history will be the ones who can have a fast, credible conversation about whether they're a candidate.

Our clinical trials page covers what the TRIUMPH programme has and hasn't measured, and the safety page covers the adverse event profile reported so far — predominantly gastrointestinal, and predominantly during dose escalation.

What we still don't know

Three honest gaps. First, no peer-reviewed retatrutide discontinuation data exists yet. Second, we don't know whether a lower maintenance dose preserves most of the benefit — that's a question the dosing arms may eventually answer, but haven't. Third, we have no Australian pricing, no TGA submission date, and no PBS pathway. Anyone publishing a confident Australian launch date is making it up.

Join the free updates list and we'll send the Australian-relevant developments — TGA movement, trial publications, funding decisions — as they actually happen.

FAQ

What happens if you stop taking retatrutide?

There is no published long-term retatrutide discontinuation study yet. Based on the closest comparable evidence — semaglutide and tirzepatide withdrawal data — significant weight regain after stopping is the expected pattern, which is why long-term planning matters before starting.

Is retatrutide available in Australia in 2026?

No. Retatrutide remains investigational and is not TGA-approved. Eli Lilly has signalled regulatory filings beginning from 2027 in the US, and Australian availability would follow a separate TGA process after that.

Will retatrutide be covered by the PBS in Australia?

There is no PBS listing and no submission to assess, because the medicine isn't registered here. Existing obesity medicines like semaglutide and tirzepatide are not PBS-subsidised for weight management alone, so out-of-pocket cost is the realistic starting assumption.

How much weight did people lose on retatrutide?

In the phase 3 TRIUMPH-1 trial, participants on the 12mg dose lost up to about 28.3% of body weight on average over 80 weeks, and 45.3% lost 30% or more. These are on-treatment results reported by Eli Lilly.

Sources

Retatrutide.net.au is an independent Australian information resource and is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company. This article is general information only and is not medical advice. Retatrutide is an investigational medicine that is not approved by the TGA and is not available for prescription in Australia. Always speak with a qualified Australian health professional about your own circumstances.